The prescription of peritoneal dialysis

被引:10
|
作者
Tzamaloukas, Antonios H. [1 ]
Raj, Dominic S. C.
Onime, Aideloje
Servilla, Karen S.
VanderJagt, Dorothy J.
Murata, Glen H.
机构
[1] New Mexico VA Hlth Care Syst, Dept Med, Renal Sect 111C, Albuquerque, NM 87108 USA
关键词
D O I
10.1111/j.1525-139X.2007.00412.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In addition to the maintenance of normal extracellular electrolyte composition, the prescription of continuous peritoneal dialysis (CPD) should address four other specific issues: (i) prevention of uremia by achievement of adequate clearance of azotemic substances, (ii) prevention of progressive expansion of the extracellular volume by adequate peritoneal ultrafiltration, (iii) prevention of loss of residual renal function, and (iv) prevention of deterioration of the peritoneal membrane structure and function. Urea clearance, in the form of Kt/V(Urea), is the index of removal of azotemic substances proposed by current guidelines. The target total (renal plus peritoneal) Kt/V(Urea) is >= 1.7 weekly. To provide the desired peritoneal Kt/V(Urea) (K(p)t/V(Urea)), the prescription of peritoneal dialysis must provide a daily drain volume (Dv) defined by the clearance equations as Dv = V x (K(p)t/V(Urea))/(D/P(Urea)), where V is body water obtained from published anthropometric formulas, K(p)t/V(Urea) = (1.7 - renal Kt/V(Urea))/7 and D/P(Urea) is the dialysate-to-plasma urea concentration ratio at the dwell time prescribed. Computer programs obtain the relevant D/P(Urea) values from formal studies of peritoneal transport. In the absence of these studies (for example, at initiation of CPD), D/P(Urea) values can be obtained from published studies with similar dwell times. Body size, indicated by V, is the major determinant of the K(p)t/V(Urea) limit provided by a given CPD schedule. Other obstacles to achievement of adequate urea clearance are created by poor patient compliance, inaccuracies of the anthropometric formulas estimating V, and mechanical complications of CPD that lead to retention of dialysate in the body. The main requirements for the prescription of adequate ultrafiltration are knowledge of the individual peritoneal transport characteristics, monitoring of urinary volume, and restriction of dietary sodium intake. Excessive dietary sodium intake is the major cause of extracellular volume expansion in CPD. Ideally, sodium intake should be kept at the level of total (peritoneal plus renal) sodium removal. Preventing the loss of residual renal function involves avoidance of nephrotoxic influences in the form of medications, radiocontrast agents, urinary obstruction and infection, and possibly other influences, such an elevated calcium-phosphorus product and anemia. Use of the lowest dialysate dextrose concentration that will allow adequate ultrafiltration is currently the most widespread practical measure of prevention of peritoneal membrane deterioration. Formulation of biocompatible dialysate is a major ongoing research effort and may greatly enhance the success of CPD in the future.
引用
收藏
页码:250 / 257
页数:8
相关论文
共 50 条
  • [31] PRESCRIPTION PLANNING FOR PERITONEAL-DIALYSIS - A PRACTICE CHALLENGE
    KRAPF, R
    ZABETAKIS, PM
    PERITONEAL DIALYSIS INTERNATIONAL, 1995, 15 (05): : S53 - S58
  • [32] Effects of initial peritoneal dialysis prescription on clinical outcomes in Japanese peritoneal dialysis patients: a cohort study
    Sakurada, Tsutomu
    Zhao, Junhui
    Tu, Charlotte
    Bieber, Brian
    Cheetham, Melissa
    Pisoni, Ronald L.
    Perl, Jeffrey
    Tsuchiya, Ken
    Kawanishi, Hideki
    Minakuchi, Jun
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [33] THE PRESCRIPTION IN PERITONEAL DIALYSIS: INTERNATIONAL COMPARISON FROM THE PERITONEAL DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (PDOPPS)
    Davies, Simon J.
    Zhao, Junhui
    Bieber, Brian
    Perl, Jeffrey
    Wilkie, Martin
    Marshall, Mark
    Kawanishi, Hideki
    Tentori, Francesca
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 240 - 241
  • [34] KINETIC MODELING AS A PRESCRIPTION AID IN PERITONEAL-DIALYSIS
    VONESH, EF
    LYSAGHT, MJ
    MORAN, J
    FARRELL, P
    BLOOD PURIFICATION, 1991, 9 (5-6) : 246 - 270
  • [35] What is the optimal automated peritoneal dialysis [APD] prescription?
    Blake, PG
    McMurray, S
    Oreopoulos, DG
    Mupas, L
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 : A1278 - A1278
  • [36] Rethinking the peritoneal dialysis prescription: Results of recent studies
    Bargman, JM
    NEPHROLOGY, 2006, 11 (02) : 85 - 89
  • [37] Peritoneal Dialysis in Children: Consider the Membrane for Optimal Prescription
    Fischbach, M.
    Dheu, C.
    Michallat, A. C.
    Escande, B.
    Laugel, V.
    Barthelmebs, M.
    Zoellner, G.
    Schaefer, F.
    Schmitt, C. P.
    Haraldsson, B.
    Helwig, J. J.
    SAUDI JOURNAL OF KIDNEY DISEASES AND TRANSPLANTATION, 2005, 16 (01) : 1 - 5
  • [38] CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) PRESCRIPTION PATTERNS IN A LARGE DIALYSIS ORGANIZATION
    Ficociello, Linda
    Parameswaran, Vidhya
    Kraus, Michael
    Chatoth, Dinesh
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (04) : S128 - S129
  • [39] CHANGES IN DIALYSIS PRESCRIPTION AFFECT THE TIME COURSE OF SOLUTE TRANSPORT IN PERITONEAL DIALYSIS
    Brenna, Irene
    Elphick, Emma
    Lambie, Mark
    Davies, Simon
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33 : 194 - 194
  • [40] Peritoneal dialysis prescription in children: bedside principles for optimal practice
    Fischbach, Michel
    Warady, Bradley A.
    PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1633 - 1642